BA
Insider
Behzad Aghazadeh
DirectorBehzad Aghazadeh (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Scribe Therapeutics Inc. (SCTX). Across 1 priced purchase filing, the average 21-session return was +73.4% from execution and +73.4% from disclosure (delay-adjusted; derived). The largest single filing was $36.3M of SCTX (2,391,238 sh across 3 lots, as filed), executed Jul 24.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+73.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+73.4%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$36.3M
shares × price, as filed
Last traded
Jul 28
Filed Jul 28
Median ADV $11.1M across their filed names
Open performance→Volume by month
Buys $36.3M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
SCTXRecent filings
SCTXPURCHASE
Scribe Therapeutics Inc.
View filing →
$36.3M2,391,238 sh across 3 lots
Exec Jul 24
Filed Jul 28 · 9:30 PM ET